Shining a light on cancer

We are developing a multi-cancer platform powered by our Dxcover AI Engine, with first application in earlier diagnosis of brain tumours.

To be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.

Data highlight high sensitivity of novel infrared spectroscopy approach for stage I disease SCOTLAND, UK., March 29, 2022 Dxcover...

Dxcover Limited, developer of liquid biopsies for the early detection of cancer, has secured US patents for its groundbreaking Dxcover®...

Dxcover Limited, developer of liquid biopsies for the early detection of cancer, has secured ISO 13485:2016 certification for its Quality...